P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 4, 2007, Pages 878-886

  Cousein, Etienne ^a   Barthélémy, Christine ^a   Poullain, Stéphanie ^b   Simon, Nicolas ^a   Lestavel, Sophie ^c   Williame, Virginie ^a   Joiris, Etienne ^a   Danel, Cécile ^a   Clavey, Véronique ^c   Brossard, Denis ^b   Robert, Hugues ^a   Crauste Manciet, Sylvie ^b   Vaccher, Claude ^a   Odou, Pascal ^a  

^a Laboratoire de Biopharmacie   (France)

^b UNIV PARIS SUD   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Caco 2 cells; CYP3A4; Efflux transport; P glycoprotein; Rats model; Risperidone

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; FENOFIBRATE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; INDOMETACIN; KETOCONAZOLE; PALIPERIDONE; RISPERIDONE; VERAPAMIL;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE PERMEABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; HUMAN; HUMAN CELL; MALE; MONOLAYER CULTURE; NONHUMAN; RAT;

EID: 34247600128     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.01.028     Document Type: Article

References (56)

1. Bachmeier C.J., and Miller D.W. A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier. Pharm Res 22 (2005) 113-121
2. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Nat Cancer Inst 92 (2000) 1295-1302
3. Boulton D.W., DeVane C.L., Liston H.L., and Markowitz J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71 (2002) 163-169
4. Brandsch M., Knutter I., and Leibach F.H. The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci 21 (2004) 53-60
5. Carrière V., Lesuffleur T., Barbat A., Rousset M., Dussaulx E., Costet P., et al. Expression of cytochrome P-450 3A in HT29-MTX cells and Caco-2 clone TC7. FEBS Lett 355 (1994) 247-250
6. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand 85 (1992) 295-305
7. Cornwell M.M., Pastan I., and Gottesman M.M. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262 (1987) 2166-2170
8. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., and Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27 (1999) 866-871
9. Draper M.P., Martell R.L., and Levy S.B. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 75 6 (1997) 810-815
10. Ejsing T.B., Pedersen A.D., and Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol Clin Exp 20 (2005) 493-500
11. Ehrhardt M., Lindenmaier H., Burhenne J., Haefeli W.E., and Weiss J. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol 67 2 (2004) 285-292
12. Ereshefsky L., and Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 3 Suppl 3 (1993) S80-S88
13. Faassen F., Vogel G., Spanings H., and Vromans H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm 263 (2003) 113-122
14. Fang J., Bourin M., and Baker G.B. Metabolism of risperidone to 9-hydroxy-risperidone by human cytochrome P450 2D6 and 3A4. Naunyn Schmiederberg's Arch Pharmacol 359 (1999) 147-151
15. Fricker G., Drewe J., Huwyler J., Gutmann H., and Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 118 (1996) 1841-1847
16. Gan L.S.L., Moseley M.A., Khosla B., Augustijns P.F., Bradshaw T.P., Hendren R.W., et al. CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 24 (1996) 344-349
17. Gao J., Murase O., Schowen R.L., Aube J., and Borchardt R.T. A functional assay for quantification of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 18 (2001) 171-176
18. Hochman J.H., Yamazaki M., Ohe T., and Lin J.H. Evaluation of drug interactions with P-Glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 3 (2002) 257-273
19. Hu M., Li Y., Davitt C.M., Huang S.M., Thummel K., Penman B.W., et al. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res 16 9 (1999) 1352-1359
20. Huang M.L., van Peer A., Woestenborghs R., de Coster R., Heykants J., Jansen A.A.J., et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54 (1993) 257-268
21. Hunter J., Hirst B.H., and Simmons N.L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10 (1993) 743-749
22. Ito K., Kusuhara H., and Sugiyama Y. Effects of intestinal CYP3A4 and P glycoprotein on oral drug absorption - theoretical approach. Pharm Res 16 (1999) 225-231
23. Jover F., Cuadrado J.M., Andreu L., and Merino J. Reversible coma cause by risperidone-ritonavir interaction. Clin Neuropharmacol 25 (2002) 251-253
24. Jung S.M., Kim K.A., Cho H.K., Jung I.G., Park P.W., Byun W.T., et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 78 5 (2005) 520-528
25. Kelly D.V., Beique L.C., and Bowmer M.I. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 36 (2002) 827-830
26. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101 (1998) 289-294
27. Lane H.Y., and Chang W.H. Risperidone-carbamazepine interactions; is cytochrome P450 3A involved?. J Clin Psychiatry 59 8 (1998) 430-431
28. Langenbucher F. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm Ind 44 11 (1982) 1166-1172
29. Leslie E.M., Deeley R.G., and Cole S.P.C. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defence. Toxicol Appl Pharmacol 204 (2005) 216-237
30. Leu B.L., and Huang J.D. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35 (1995) 432-436
31. Li Q., Tsuji H., Kato Y., Sai Y., Kubo Y., and Tsuji A. Characterization of the transdermal transport of flurbiprofen and indomethacin. J Control Release 110 3 (2006) 542-556 [21]
32. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., et al. Role of intestinal glycoprotein (mdr-1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62 (1997) 248-260
33. Masereeuw R., van Pelt A.P., van Os S.H., Willems P.H., Smits P., and Russel F.G. Probenecid interferes with renal oxidative metabolism: a potential pitfall in its use as an inhibitor of drug transport. Br J Pharmacol 131 1 (2000) 57-62
34. Meuldermans W., Hendrickx J., Mannens G., Lavrijsen K., Janssen C., Bracke J., et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos 22 1 (1994) 129-138
35. Nakagami T., Yasui-Furukori N., Saito M., Tateishi T., and Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 78 (2005) 43-51
36. Odou P., Levron J.C., Luyckx M., Brunet C., and Robert H. Risperidone drug monitoring, a useful clinical tool?. Clin Drug Invest 19 4 (2000) 283-292
37. Petri N., Tannergren C., Rungstad D., and Lennernäs H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 21 (2004) 1398-1404
38. Prior T.I., and Baker G.B. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28 (2003) 99-112
39. Salphati L., and Benet L.Z. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56 (1998) 308-313
40. Sandstrom R., Karlsson A., and Lennernas H. The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum. J Pharm Pharmacol 50 (1988) 729-735
41. Schmiedlin-Ren P., Thummel K.E., Fisher J.M., Paine M.F., and Watkins P.B. Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos 29 (2001) 1446-1453
42. Shiraki N., Hamada A., Yasuda K., Fujii J., Arimori K., and Nakano M. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol Pharm Bull 23 12 (2000) 1528-1531
43. Takano M., Hasegawa R., Fukuda T., Yumoto R., Nagai J., and Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358 (1998) 289-294
44. Takara K., Tanigawara Y., Komada F., Nishiguchi K., Sakaeda T., and Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein mediated resistance of anticancer drugs. Biol Pharm Bull 22 (1999) 1355-1359
45. Troutman M.D., and Thakker D.R. The efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport - asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2-cell monolayers. Pharm Res 20 (2003) 1200-1209
46. Troutman M.D., and Thakker D.R. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20 (2003) 1210-1224
47. Wacher V.J., Silverman J.A., Zhang Y., and Benet L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87 (1998) 1322-1330
48. Waeldele G., and Stoclet J.C. Permanent catheterization of the thoracic aorta. Direct measure of blood pressure, injection of substances and blood sampling in the waking rat. J Physiol (Paris) 66 3 (1973) 357-366
49. Wagner J.G., and Nelson E. Percent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci 52 (1963) 610-611
50. Wang J.S., Ruan Y., Taylor R.M., Donovan J.L., Markowitz J.S., and DeVane C.L. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7 (2004) 415-419
51. Wang J.S., Zhu H.J., Markowitz J.S., Donovan J.L., and DeVane C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 187 4 (2006) 415-423
52. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27 (1997) 161-170
53. 2+ channel blockers. Antimicrob Agents Chemother 46 (2002) 1375-1380
54. Yamazaki M., Akiyama S., Ni'inuma K., Nishigaki R., and Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 25 (1997) 1123-1129
55. Yasui-Furukori N., Hidestrand M., Spina E., Facciola G., Scordo M.G., and Tybring G. Different enantioselective 9-Hydroxylation of risperidone by the two human CYP2D6 and CYP 4A4 enzymes. Drug Metab Dispos 29 10 (2001) 1263-1268
56. Zhu H.J., Wang J.S., Markowitz J.S., Donovan J.L., Gibson B.B., and Devane C.L. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology (2006) Aug 23; [Epub ahead of print]